© Copyright Acquisition International 2024 - All Rights Reserved.

Article Image - Evotec Announces Its Intent to Acquire Cyprotex Plc
Posted 26th October 2016

Evotec Announces Its Intent to Acquire Cyprotex Plc

Acquisition would add world-leading high-quality ADME-Tox services and strengthen Evotec's leadership in drug discovery

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Evotec Announces Its Intent to Acquire Cyprotex Plc
Image

Evotec Announces Its Intent to Acquire Cyprotex Plc

Acquisition would add world-leading high-quality ADME-Tox services and strengthen Evotec’s leadership in drug discovery

– Evotec will pay approximately £ 55.36 m (EUR 62.00 m) in cash for the full share capital of Cyprotex and funding of all existing debt of the AIM-listed company

– Proposed acquisition, unanimously recommended by the board of Cyprotex, is expected to close before year-end 2016

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that it has made an offer to acquire Cyprotex PLC (“Cyprotex”, AIM: CRX-GB), a specialist pre-clinical contract research organisation in ADME-Tox and DMPK. Cyprotex serves the industry’s increasing requirement for earlier drug screening, regulatory requirements and reducing the reliance on animal testing.

The proposed acquisition, which has been unanimously recommended by the board of Cyprotex, is expected to close before year-end 2016. Evotec will pay approximately £ 55.36 m (EUR 62.00 m; £/EUR exchange rate of 1.12) in cash for the acquisition of all 26.1 million issued and to be issued Cyprotex shares and the funding of all existing company debt. The offer of 1.60 £ per Cyprotex share reflects a 9.4% premium to the VWAP of the past 30 trading days at AIM. The offer is intended to be implemented by a scheme of arrangement regulated by the UK takeover code, with already >50% shares secured irrevocable. The acquisition will add to Evotec’s revenues and be accretive to Evotec’s 2017 EBITDA.

Cyprotex is the world’s largest contract research organisation specialising in pre-clinical ADME-Tox and DMPK serving the Pharmaceutical, Chemical, Agrochemical and Cosmetics markets. Cyprotex, headquartered in the UK, was founded in 1999 and is publicly traded on AIM (CRX). It has 136 employees working from sites at Macclesfield and Alderley Park, both of which are located near Manchester in the UK, and at Watertown, MA, and Kalamazoo, MI, in the USA. With more than 1,500 partners, Cyprotex has a very strong customer network. Cyprotex reported H1 2016 revenues of £ 8.73 m (EUR 9.78 m) (H1 2015: £ 6.93 m (EUR 7.76 m)) with an underlying EBITDA of £ 2.34 m (EUR 2.62 m) (H1 2015: £ 1.10 m (EUR 1.23 m)).

Sharpening Evotec’s leadership role in drug discovery The acquisition strengthens Evotec’s high-end drug discovery platform and capabilities with access to the market’s most industrialised ADME-Tox platform and proven expertise in in vitro ADME screening, mechanistic and high-content toxicology screening and predictive modelling.

This perfectly augments Evotec’s drive for innovation efficiency in drug discovery by enabling its partners to make early informed decisions on a molecule’s suitability for further development. The Cyprotex platform can be leveraged in a high-throughput manner or to support integrated drug discovery projects.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: “The ability to test or predict a molecule’s suitability as a drug at an early stage is critical in the drive to increase the efficiency of drug discovery.

The proposed acquisition of Cyprotex is a completely logical step to strengthen Evotec’s position as the world’s leading partner of choice for driving such efficiencies in drug discovery to the industry. The proven technology platform of Cyprotex and its expert and dedicated employees will be a strong addition to our best-in-class drug discovery platform and resources. We also expect that both organisations will leverage their extensive partner networks to identify further commercial synergies.”

Dr Werner Lanthaler, Chief Executive Officer of Evotec, added: “Our focus to make the most innovative and capital efficient drug discovery platform will be perfectly extended by Cyprotex. Given our strong performance over the last years, a very good outlook of our business into the coming years, and the commercial profile of Cyprotex we also feel very comfortable in using the cash on our strong balance sheet for this accretive acquisition. We are very much looking forward to welcoming the employees of Cyprotex within the Evotec Group after closing of the transaction.”

Categories: Innovation, Leadership


You Might Also Like
Read Full PostRead - Eye Icon
BPO and Technology Acquires top Provider in Marketing Communications
Finance
20/01/2016BPO and Technology Acquires top Provider in Marketing Communications

Headquartered in New York City, Smart Source's acquisition allows these two dynamic companies to combine best practices, services and technologies to offer the most elevated client experience in brand management, marketing and communications to clients nationw

Read Full PostRead - Eye Icon
Strong Management More Important Than Ever in UK
Innovation
29/10/2019Strong Management More Important Than Ever in UK

We are experiencing a resurgence in the popularity of tough bosses in the UK. The “Imperial CEO” started to become less fashionable in the eighties with the decline in deference. The nineties saw the reputation of strong business leadership tarnished with

Read Full PostRead - Eye Icon
5 Ways In Which mLearning Enhances Employee Engagement
Innovation
29/09/20225 Ways In Which mLearning Enhances Employee Engagement

There is no doubt that mobile phones have deeply entwined into our daily lives. They fulfill a wide variety of needs, from allowing us to consume quality training sessions to the ability to capture special moments or ordering our favorite dessert.

Read Full PostRead - Eye Icon
Microsemi Successfully Completes Acquisition of Vitesse
Finance
30/04/2015Microsemi Successfully Completes Acquisition of Vitesse

Microsemi Corporation, a leading provider of semiconductor solutions differentiated by power, security, reliability and performance, and Vitesse Semiconductor Corporation jointly announced today that Microsemi's wholly-owned subsidiary LLIU100 Acquisition Corp

Read Full PostRead - Eye Icon
Abundant Opportunities in Botswana
Finance
05/12/2016Abundant Opportunities in Botswana

BDC is a development finance Institution tasked with the industrialisation of Botswana.

Read Full PostRead - Eye Icon
4 Essential Components of Power Plant Maintenance
Innovation
25/11/20214 Essential Components of Power Plant Maintenance

Power plant maintenance aims at supporting a smooth workflow in a power plant. It involves procedures such as routine inspection, equipment adjustment, repair or replacement, and general systems integration and monitoring.

Read Full PostRead - Eye Icon
CREALOGIX’s acquisition of MBA Systems
Finance
19/03/2015CREALOGIX’s acquisition of MBA Systems

CREALOGIX has acquired MBA Systems, a well-established UK fintech brand and leading supplier of innovative web-based solutions and services to the securities and wealth management industries. With this move, CREALOGIX - the Swiss based technology group ranked

Read Full PostRead - Eye Icon
Copperstone Capital
Finance
28/10/2015Copperstone Capital

Copperstone Capital is an investment management firm founded in 2010 in Moscow by David Amaryan.Copperstone Capital manages wealth for high net worth individuals and institutions and provides advisory services.

Read Full PostRead - Eye Icon
Brewing the Way Forward!
Innovation
30/04/2015Brewing the Way Forward!

Nils Oscar Brewing Company is the largest independent Craft brewery in Sweden in terms of turnover and production volume. We find out from CEO, Jonas Kandefelt, what’s next for the fast-growing firm?



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have 14 unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow